KAZIA THERAPEUTICS
Kazia Therapeutics is an oncology focused biotechnology company, developing innovative anti-cancer drugs. Kazia Therapeutics collaborates with leading scientists, clinicians and investors around the world.
KAZIA THERAPEUTICS
Industry:
Biotechnology Clinical Trials Commercial Innovation Management Pharmaceutical
Founded:
1994-01-01
Address:
Hornsby, New South Wales, Australia
Country:
Australia
Website Url:
http://www.kaziatherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+61 2 9472 4100
Email Addresses:
[email protected]
Total Funding:
5.65 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS DoubleClick.Net Sendgrid Facebook CDN JW Player Platform WebCentral MailGuard
Similar Organizations
Basilea Pharmaceutica
Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company.
Glioblast Pty Ltd
Glioblast Pty Ltd is a neuro-oncology-focused biotechnology company.
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotechnology company.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
KBP Biosciences
A multinational clinical stage biotechnology company.
Panacea Biotec
Panacea Biotec is an Innovation driven Biotechnology company.
Relief Therapeutics
Relief Therapeutics is a clinical stage biotechnology company.
Salarius Pharmaceuticals
Salarius Pharmaceuticals is an oncology based biotechnology company.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-10-31 | Glioblast Pty Ltd | Glioblast Pty Ltd acquired by Kazia Therapeutics | 1.6 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-13 | Kazia Therapeutics (KZIA): Karen Krumeich Named As CFO |
| 2021-11-15 | Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer |
Official Site Inspections
http://www.kaziatherapeutics.com Semrush global rank: 1.16 M Semrush visits lastest month: 27.1 K
- Host name: a290d26420470737c.awsglobalaccelerator.com
- IP address: 15.197.133.181
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Kazia Therapeutics"
About Us | Kazia Therapeutics Limited
Kazia Therapeutics Limited Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000, Australia [email protected] https://www.kaziatherapeutics.comSee details»
KAZIA CORPORATE UPDATE AND CORPORATE PRESENTATION
Www.kaziatherapeutics.com or follow us on Twitter @KaziaTx. This document was authorized for release to the ASX by John Friend, Chief Executive Officer. Forward-Looking Statements . …See details»
Kazia Therapeutics Limited - LinkedIn
Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company. Our lead program is paxalisib, which is being developed to treat glioblastoma (GBM), the most …See details»
Kazia Therapeutics Limited (KZIA)
See the company profile for Kazia Therapeutics Limited (KZIA) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Kazia Therapeutics Limited (KZIA) Company Profile & Overview
Jan 6, 1999 Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a …See details»
KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM …
Jul 6, 2023 For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx. This document was authorized for release by John Friend, MD, Chief Executive …See details»
Kazia Therapeutics Limited (KZIA) - Yahoo Finance
See the company profile for Kazia Therapeutics Limited (KZIA), including business summary, industry/sector information, number of employees, corporate governance, key executives and …See details»
Kazia Therapeutics Ltd, KZIA:NAQ profile - FT.com - Financial Times
Nov 27, 2024 Kazia Therapeutics Ltd (KZIA:NAQ) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.See details»
For Investors | Kazia Therapeutics Limited
Kazia is an Australian oncology company developing innovative, high-impact drugs for cancer. Our lead program is paxalisib, which is being developed to treat glioblastoma, the most …See details»
Kazia Therapeutics Announces Granting of Type C Meeting with …
Nov 5, 2024 For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx. Forward-Looking Statements This announcement may contain forward-looking …See details»
Kazia Therapeutics Provides Update on Paxalisib Regulatory …
4 days ago For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx. Forward-Looking Statements. This announcement may contain forward-looking …See details»
Kazia Therapeutics Announces Granting of Type C Meeting with …
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced that the U.S. Food and Drug Administration (FDA) has granted a Type C meeting …See details»
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After ...
Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early conclusion based on positive safety and promising clinical …See details»
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for ...
Adaptive Research (GCAR), a nonprofit organization comprised of some of the world’s foremost clinical, translational, and basic science researchers, from institutions such as ... For more …See details»
Kazia Therapeutics Announces Granting of Type C Meeting with …
Nov 4, 2024 For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx. Forward-Looking Statements. This announcement may contain forward-looking …See details»
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for ...
Jul 10, 2024 GBM AGILE is an adaptive phase II/III global trial sponsored by the Global Coalition for Adaptive Research (GCAR), a nonprofit organization comprised of some of the world's …See details»
Kazia Therapeutics Provides Update on Paxalisib Regulatory …
4 days ago Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of …See details»
For Investors | Kazia Therapeutics Limited
Kazia Therapeutics Limited Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000, Australia [email protected] https://www.kaziatherapeutics.comSee details»
Kazia Therapeutics - Craft
Kazia Therapeutics is an oncology-focused biotechnology company developing anti-cancer drugs. Its lead program, GDC-0084, is developed to treat aggressive brain cancer (glioblastoma …See details»
Kazia Therapeutics - PitchBook
Kazia Therapeutics General Information Description. Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing …See details»